Amicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of ($0.02), $0.04 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $110.4 million versus the consensus estimate of $112.39 million.

Guidance

Total Revenue Growth - 25% to 30%

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.